HK1207312A1 - 溫度穩定性疫苗製劑 - Google Patents

溫度穩定性疫苗製劑

Info

Publication number
HK1207312A1
HK1207312A1 HK15108032.6A HK15108032A HK1207312A1 HK 1207312 A1 HK1207312 A1 HK 1207312A1 HK 15108032 A HK15108032 A HK 15108032A HK 1207312 A1 HK1207312 A1 HK 1207312A1
Authority
HK
Hong Kong
Prior art keywords
vaccine formulations
temperature stable
stable vaccine
formulations
temperature
Prior art date
Application number
HK15108032.6A
Other languages
English (en)
Inventor
‧盧克
‧魯伊斯
‧麥爾斯
‧韋爾奇
Original Assignee
Emergent Product Dev Gaithersburg Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergent Product Dev Gaithersburg Inc filed Critical Emergent Product Dev Gaithersburg Inc
Publication of HK1207312A1 publication Critical patent/HK1207312A1/zh

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/07—Bacillus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Peptides Or Proteins (AREA)
HK15108032.6A 2012-06-25 2015-08-19 溫度穩定性疫苗製劑 HK1207312A1 (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261664062P 2012-06-25 2012-06-25
US201361801385P 2013-03-15 2013-03-15
PCT/US2013/047712 WO2014004578A1 (en) 2012-06-25 2013-06-25 Temperature stable vaccine formulations

Publications (1)

Publication Number Publication Date
HK1207312A1 true HK1207312A1 (zh) 2016-01-29

Family

ID=49783811

Family Applications (1)

Application Number Title Priority Date Filing Date
HK15108032.6A HK1207312A1 (zh) 2012-06-25 2015-08-19 溫度穩定性疫苗製劑

Country Status (13)

Country Link
US (1) US20150335752A1 (zh)
EP (1) EP2863898A4 (zh)
JP (1) JP2015525748A (zh)
KR (1) KR20150034170A (zh)
CN (1) CN104470506A (zh)
AU (1) AU2013280480B2 (zh)
CA (1) CA2877130A1 (zh)
HK (1) HK1207312A1 (zh)
IL (1) IL236380A0 (zh)
IN (1) IN2015MN00038A (zh)
RU (1) RU2014151424A (zh)
SG (1) SG11201408262XA (zh)
WO (1) WO2014004578A1 (zh)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3086780A4 (en) 2013-12-27 2017-08-09 Emergent Product Development Gaithersburg Inc. Temperature stable vaccine formulations
JP6741580B2 (ja) * 2013-12-31 2020-08-19 インフェクシャス ディズィーズ リサーチ インスティチュート 単一バイアルのワクチン製剤
US20170007690A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of anthrax recombinant protective antigen
US11173197B2 (en) 2015-07-07 2021-11-16 Bluewillow Biologics, Inc. Methods and compositions for nanoemulsion vaccine formulations
US20170007694A1 (en) * 2015-07-07 2017-01-12 Nanobio Corporation Methods and compositions for the stabilization of proteins
KR20190053908A (ko) 2016-09-16 2019-05-20 로이코케어 아게 가공 동안 바이오 의약품의 안정화를 위한 신규한 방법
WO2018050873A1 (en) 2016-09-16 2018-03-22 Leukocare Ag A novel method for producing low viscous and highly concentrated biopharmaceutical drug products in liquid formulation
KR101744900B1 (ko) 2017-01-20 2017-06-08 주식회사 대웅 보툴리눔 독소를 포함하는 안정한 액상 조성물

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4142095B2 (ja) * 1994-06-02 2008-08-27 クアドラント・ドラツグ・デリバリー・リミテツド 各種物質の再水和または融解時の凝集を防止する方法及び該方法により得られる組成物
US7201912B2 (en) * 2002-04-12 2007-04-10 Emergent Biodefense Operation Lansing Inc. Recombinant immunogenic compositions and methods for protecting against lethal infections from Bacillus anthracis
US9283260B2 (en) * 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
CN100556400C (zh) * 2006-07-20 2009-11-04 上海交通大学 载有活性疫苗或抗体的多糖玻璃体微粒的制备方法
WO2008079464A2 (en) * 2006-09-08 2008-07-03 Becton, Dickinson And Company Stable powder formulations of alum-adsorbed vaccines
EP2829282B1 (en) * 2007-03-22 2017-10-25 The Regents of The University of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
US8778359B2 (en) * 2008-07-30 2014-07-15 Emergent Biosolutions Inc. Stable anthrax vaccine formulations
US20110212127A1 (en) * 2008-09-24 2011-09-01 Stabilitech Ltd. Method for Preserving Polypeptides Using a Sugar and Polyethyleneimine
AU2009338516A1 (en) * 2009-01-22 2011-08-18 Pharmathene, Inc. Stable vaccine compositions and methods of use

Also Published As

Publication number Publication date
SG11201408262XA (en) 2015-01-29
EP2863898A1 (en) 2015-04-29
AU2013280480B2 (en) 2018-03-15
CA2877130A1 (en) 2014-01-03
AU2013280480A1 (en) 2015-01-22
EP2863898A4 (en) 2016-04-27
IL236380A0 (en) 2015-02-26
IN2015MN00038A (zh) 2015-10-16
JP2015525748A (ja) 2015-09-07
WO2014004578A1 (en) 2014-01-03
KR20150034170A (ko) 2015-04-02
RU2014151424A (ru) 2016-08-20
CN104470506A (zh) 2015-03-25
US20150335752A1 (en) 2015-11-26

Similar Documents

Publication Publication Date Title
HK1212701A1 (zh) 恩雜魯胺製劑
HK1207967A1 (zh) 疫苗
HK1212906A1 (zh) 疫苗組合物
HK1203812A1 (zh) 新型藥物製劑
PL2647387T3 (pl) Kompozycja szczepionki
HK1207312A1 (zh) 溫度穩定性疫苗製劑
EP2876161A4 (en) VACCINE
GB201223386D0 (en) Vaccine
EP2755680A4 (en) PARTICULATE VACCINE FORMULATIONS
EP2934482A4 (en) ADMINISTRATIVE FORMULATIONS
ZA201306000B (en) Stable formulation
PL2644189T3 (pl) Stabilne formulacje bortezomibu
PT2908835T (pt) Formulações estáveis
GB201210530D0 (en) Extended release formulations
EP2822599A4 (en) VACCINE
HK1213949A1 (zh) 活疫苗製備
PL2908859T3 (pl) Formulacje arypiprazolu
EP3086780A4 (en) Temperature stable vaccine formulations
HK1209339A1 (zh) 藥物配方
GB201202090D0 (en) Vaccine
GB201206178D0 (en) Formulations
GB201217321D0 (en) Vaccine
GB201210226D0 (en) Vaccine
GB201206169D0 (en) Vaccine
GB201205599D0 (en) Vaccine